Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Current Assets (2023 - 2026)

Beta Bionics' Current Assets history spans 4 years, with the latest figure at $248.0 million for Q1 2026.

  • On a quarterly basis, Current Assets fell 5.32% to $248.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $248.0 million, a 5.32% decrease, with the full-year FY2025 number at $267.9 million, up 101.55% from a year prior.
  • Current Assets hit $248.0 million in Q1 2026 for Beta Bionics, down from $267.9 million in the prior quarter.
  • Over the last five years, Current Assets for BBNX hit a ceiling of $286.1 million in Q2 2025 and a floor of $103.6 million in Q4 2023.
  • Historically, Current Assets has averaged $224.4 million across 4 years, with a median of $261.9 million in 2025.
  • Biggest five-year swings in Current Assets: surged 101.55% in 2025 and later fell 5.32% in 2026.
  • Tracing BBNX's Current Assets over 4 years: stood at $103.6 million in 2023, then grew by 28.28% to $132.9 million in 2024, then surged by 101.55% to $267.9 million in 2025, then fell by 7.44% to $248.0 million in 2026.
  • Business Quant data shows Current Assets for BBNX at $248.0 million in Q1 2026, $267.9 million in Q4 2025, and $270.0 million in Q3 2025.